Stockreport

Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC

Rani Therapeutics Holdings, Inc. - Class A  (RANI) 
PDF - Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration - [Read more]